Cardiac Ablation Market Size & Share, by Technology (Radiofrequency, Electrical, Cryoablation, Ultrasound, Microwave); Product (Irreversible Electroporation, HIFU, MRgFUS); Application (Cardiac Arrhythmia, Atrial Fibrillation, Tachycardia, Open Surgery) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4773
  • Published Date: Mar 30, 2023
  • Report Format: PDF, PPT

Companies Dominating the Cardiac Ablation Landscape

top-features-companies
    • Medtronic
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • AngioDynamics
    • Atricure, Inc.
    • Alcon
    • Boston Scientific Corporation
    • Olympus Corporation
    • CONMED Corporation
    • Medical Device Business Services, Inc.
    • BIOTRONIK SE & Co KG
    • Biosense Webster, Inc.

Browse Key Market Insights with Data Illustration:

In the News

  • Medtronic, announced the signing of a formal agreement to purchase Affera, Inc., a privately held medical technology business situated in the Boston region. For the treatment of patients with cardiac arrhythmias (irregular heartbeats) such atrial fibrillation, Affera develops and produces catheter-based cardiac ablation technologies, such as a unique localized pulsed field ablation solution (AF).

  •  Biosense Webster, Inc., a subsidiary of Johnson & Johnson MedTech, announced the availability of the OCTARAY Mapping Catheter with TRUEref Technology, which is driven by the CARTO 3 Version 7 System. Atrial fibrillation and other cardiac arrhythmias were produced using the OCTARAY Mapping Catheter (AFib).


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4773
  • Published Date: Mar 30, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are growing prevalence of diabetes mellitus, rising geriatric population, surge in investment in healthcare sector, and others.

The market is anticipated to attain a CAGR of 13% over the forecast period, i.e., 2023-2035.

Stringent government regulations, risk associated with cardiac ablation, and high cost of the treatment are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are AngioDynamics, Atricure, Inc., Alcon, Boston Scientific Corporation, Olympus Corporation, CONMED Corporation, Medical Device Business Services, Inc., BIOTRONIK SE & Co KG, Biosense Webster, Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by technology, product, application, and by region.

The atrial fibrillation segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying